AXIOS October 2, 2022
Alison Snyder

Competition is intensifying in the DNA sequencing industry, which has long been dominated by sequencing behemoth Illumina.

Driving the news: Illumina, which has an estimated 80% share of the global gene sequencing market, unveiled a new line of instruments today that it says will cut the cost of genome sequencing — the latest in a flurry of announcements from an industry in pursuit of faster and cheaper offerings.

What they’re saying: “It’s Illumina’s response to the competition,” says Jay Shendure, a professor of genome sciences at the University of Washington.

  • Element Biosciences, a startup with a benchtop sequencer already on the market, announced updated specifications this week that CEO Molly He says will support its market play to offer...

Today's Sponsors

LEK
Teladoc Health
Amwell

Today's Sponsors

LEK
Teladoc Health

Today's Sponsor

Oliver Wyman

 
Topics: Patient / Consumer, Pharma / Biotech, Precision Medicine, Provider
DNA that was frozen for 2 million years has been sequenced
How internalizing genomics can help providers achieve key healthcare goals
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
Teaming Up Two Biotech Winners to Fight Cancer: CRISPR and CAR T
Holy Grail Of Precision Medicine - Co-Development Of Therapeutics And Companion Diagnostics - Hasn’t Yet Achieved Its Potential